Passing on Topotarget A/S Annual General Meeting

4/11/2012 12:00 PM EST

Topotarget
Company Announcement

Passing on Topotarget A/S Annual General Meeting

To NASDAQ OMX Copenhagen A/S
Announcement No. 06-12 / Copenhagen, April 11, 2012


Copenhagen, Denmark – April 11, 2012 – Topotarget A/S (NASDAQ OMX: TOPO) held
its Annual General Meeting today at Symbion, Fruebjergvej 3, DK-2100 Copenhagen
Ø. 


At the meeting, Chairman of the board, Bo Jesper Hansen, and Chief Executive
Officer, Francois Martelet, gave a report on the company's activities during
the past year. The audited annual report was adopted and a resolution was
passed to discharge the Board of Directors and the management from liability.
It was resolved that the loss for the year of DKK 33 million be carried forward
to next year through recognition in retained earnings. 


Bo Jesper Hansen, Anker Lundemose, Ingelise Saunders, Jeffrey H. Buchalter, Per
Samuelsson, Gisela Schwab, and Karsten Witt were re-elected for a period of one
year. Deloitte, Statsautoriseret Revisionsaktieselskab was re-appointed as the
company's auditors. 


The Board of Directors was authorized to purchase treasury shares within a
limit of 10% of the company’s share capital at a price corresponding to the
listed price plus/less 5% at the time of the purchase. The Chairman of the
meeting was authorized to apply for registration of the resolutions passed and
to make any such amendments thereto as may be required by the Danish Commerce
and Companies Agency as a condition for registration or approval. 


Immediately after the general meeting the Board of Directors convened and
elected Bo Jesper Hansen as Chairman. 



Topotarget A/S

For further information, please contact:

Francois Martelet, CEO             Direct: +45 39 17 83 41; Mobile: +45 51 32
83 41 

Anders Vadsholt, CFO              Direct: +45 39 17 83 45; Mobile: +45 28 98 90
55 

Axel Mescheder, CMDO            Direct: +45 39 17 83 14; Mobile: +45 51 55 71 66



Background information

About Topotarget
Topotarget (NASDAQ-OMX: TOPO) is an international biopharmaceutical company
headquartered in Copenhagen, Denmark, dedicated to clinical development and
registration of oncology products. Topotarget focuses, in collaboration with
Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its
lead drug candidate, belinostat, which has shown positive results as a
monotherapy treating hematological malignancies and positive results in solid
tumors. Belinostat may be used in combination with full doses of chemotherapy,
and is in a pivotal trial within PTCL (peripheral T-cell lymphoma). For more
information, please refer to www.topotarget.com. 



Topotarget A/S Safe Harbor Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget A/S cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget A/S will not proceed as planned for technical, scientific or
commercial reasons or due to patient enrolment issues or based on new
information from non-clinical or clinical studies or from other sources; the
success of competing products and technologies; technological uncertainty and
product development risks;  uncertainty of additional funding; Topotarget A/S'
history of incurring losses and the uncertainty of achieving profitability;
Topotarget A/S' stage of development as a biopharmaceutical company; government
regulation; patent infringement claims against Topotarget A/S' products,
processes and technologies; the ability to protect Topotarget A/S' patents and
proprietary rights; uncertainties relating to commercialization rights; and
product liability exposure. We disclaim any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by law.